\
&
Contact us
Published on | 1 month ago
ProgrammesOn 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products.
This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware and software products to ensure compliance with the EU Cyber Resilience Act (CRA).
As part of the first round of financial support measures offered by the SECURE project, MSMEs may request a maximum of EUR 30.000 co-funding for certain activities, such as
Deadline to submit requests is 29 March 2026. More information on this first call can be found on the project website.
Background:
The CRA introduces mandatory cybersecurity requirements for manufacturers, covering the planning, design, development and maintenance of such products. The CRA will start to apply on 11 December 2027.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.